Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Peoples Financial Services CORP.

Peoples Financial Services CORP. decreased its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 1.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 20,226 shares of the biopharmaceutical company’s stock after selling 255 shares during the period. Peoples Financial Services CORP.’s holdings in Bristol-Myers Squibb were worth $1,144,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Pines Wealth Management LLC acquired a new stake in Bristol-Myers Squibb in the fourth quarter valued at about $235,000. SeaCrest Wealth Management LLC lifted its position in Bristol-Myers Squibb by 13.8% in the fourth quarter. SeaCrest Wealth Management LLC now owns 24,101 shares of the biopharmaceutical company’s stock valued at $1,363,000 after purchasing an additional 2,927 shares during the period. Accurate Wealth Management LLC lifted its position in Bristol-Myers Squibb by 47.0% in the fourth quarter. Accurate Wealth Management LLC now owns 6,140 shares of the biopharmaceutical company’s stock valued at $343,000 after purchasing an additional 1,963 shares during the period. 626 Financial LLC lifted its position in Bristol-Myers Squibb by 7.5% in the fourth quarter. 626 Financial LLC now owns 10,053 shares of the biopharmaceutical company’s stock valued at $569,000 after purchasing an additional 699 shares during the period. Finally, Quantum Financial Advisors LLC acquired a new stake in Bristol-Myers Squibb in the fourth quarter valued at about $293,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insider Activity at Bristol-Myers Squibb

In related news, SVP Phil M. Holzer sold 700 shares of Bristol-Myers Squibb stock in a transaction on Monday, November 4th. The shares were sold at an average price of $55.62, for a total transaction of $38,934.00. Following the transaction, the senior vice president now owns 11,760 shares in the company, valued at approximately $654,091.20. The trade was a 5.62 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Samit Hirawat bought 1,830 shares of Bristol-Myers Squibb stock in a transaction that occurred on Friday, November 1st. The shares were acquired at an average price of $54.67 per share, for a total transaction of $100,046.10. Following the acquisition, the executive vice president now directly owns 62,109 shares in the company, valued at approximately $3,395,499.03. This represents a 3.04 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Stock Up 0.7 %

Shares of BMY opened at $55.73 on Wednesday. The firm has a market cap of $113.03 billion, a PE ratio of -15.52, a price-to-earnings-growth ratio of 15.20 and a beta of 0.45. The company’s fifty day moving average is $57.44 and its two-hundred day moving average is $51.76. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $61.08. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.31. The company had revenue of $11.89 billion for the quarter, compared to analyst estimates of $11.26 billion. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. Bristol-Myers Squibb’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same quarter last year, the business earned $2.00 EPS. Analysts forecast that Bristol-Myers Squibb will post 0.93 earnings per share for the current year.

Bristol-Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd will be issued a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.45%. The ex-dividend date is Friday, January 3rd. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -69.08%.

Analyst Ratings Changes

A number of brokerages have issued reports on BMY. Leerink Partnrs raised shares of Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 12th. Bank of America reaffirmed a “neutral” rating and issued a $63.00 target price on shares of Bristol-Myers Squibb in a report on Tuesday, December 10th. Wolfe Research began coverage on shares of Bristol-Myers Squibb in a report on Friday, November 15th. They issued a “peer perform” rating for the company. Sanford C. Bernstein began coverage on shares of Bristol-Myers Squibb in a report on Thursday, October 17th. They issued a “market perform” rating and a $56.00 target price for the company. Finally, Morgan Stanley increased their target price on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the company an “underweight” rating in a report on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, four have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $56.27.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.